New results show that Medlab's flagship cannabis drug, NanaBis, achieves meaningful pain reduction in patients with breast or prostate cancers.

NanaBis is the company's cannabis-based pain management product, comprised of a proprietary 1:1 blend of highly purified cannabidiol (CBD) and tetrahydrocannabinol (THC) molecules. NanaBis was developed as a pain management alternative to traditional opioids—particularly for patients suffering from advanced types of cancer and chronic pain.

The clinical trial was designed to investigate the pain management of patients with metastatic cancers, and it found that NanaBis™ was safe, tolerable, efficacious and that dosage tolerance was achieved at 60% of the maximum dosage.

Source: Medlab Clinical's NanaBis Presentation

NanaBis™ also demonstrated to be fast-acting, with maximum concentration in serum to be 54 minutes.

The company met many of its targetted Secondary Endpoints, namely that the total patient cohort had meaningful pain reduction, with those suffering from breast or prostate cancers with bone metastasis reporting an average of 40% improvement in pain scores from baseline.

Breast or prostate cancers with bone metastasis showed a significant decrease in their use of dispensed opioid analgesics, also known as "breakthrough drugs" which are typically used when pain symptoms arise.

The company intends to use these results in order to launch MDC into its Phase 3 designs, specifically in the patient group with metastatic bone pain where breast or prostate are the primary cancers.

MDC's announcement mentions that there are an estimated 600,000 patients suffering from metastatic breast or prostate cancers in the USA, Canada, Europe and Australia who have "high unmet needs" as of 2017. Since the completion of the Trial, the majority of patients involved have elected and approved to continue using NanaBis™ free of charge.

Dr Sean Hall, CEO of MDC states, "with a strong trial design, that involved a professional and strong clinical trial team and collaborators, today we have primary evidence that NanaBis™ is safe, tolerable and provided a significant benefit in managing pain associated with metastatic cancers. There were a number of notable secondary gains, one of the biggest worth mentioning was a drastic reduction of breakthrough medication used by those patients with breast or prostate cancers with bone METs."

We can confidently argue, NanaBis™ has a strong indication for use in pain management and is a compelling therapy for this patient group.

Dr Sean Hall, CEO of Medlab Clinical

Professor Luis Vitetta, Director of Medical Research at MDC states, "the completion of Medlab's SAD/MAD clinical study with NanaBis™ in advanced cancer pain management has proven safe. Furthermore, the results relevant to pain management provides information that allows progression to the next phase of NanaBis™' development. The design of a robust Phase 3 clinical study and it's successful completion will advance the path toward registration for NanaBis™, as an alternative analgesic medication."

Moving forward, Medlab will undertake a secondary evaluation of the data whilst preparing for the upcoming Phase 3 clinical trials. To learn more about Medlab Clinical, visit the company HQ here. You can also find the company's recent presentation on NanaBis here.

I want to learn more about…

CannabisLatest Stock Picks

I want to learn more about…

CannabisLatest Stock Picks

The Green Fund is Asia Pacific's preeminent media house, positioned at the forefront of the global cannabis industry. Committed to driving the industry forward, we spotlight the sector from all angles, explore the companies and the players making headlines, and cover some of the biggest cannabis companies in the world.

Any financial product advice provided in this website is general in nature. Content on this website does not take into account the objectives, financial situation or needs of any person, or purport to be comprehensive or constitute investment advice and should not be relied upon as such. You should consult a professional adviser to help you form your own opinion of the information and on whether the information is suitable for your individual objectives and needs as an investor. Where necessary, you should obtain a Product Disclosure Statement relating to the product and consider it before making any decision about whether to acquire the product. Read More

The content of this website does not constitute an offer by any representative of The Green Fund to buy or sell any financial products or services. Accordingly, reliance should not be placed solely on the content of this website, including any reports or recommendations, as the basis for making an investment, financial or other decision.

Recipients should not act on any report or recommendation issued by The Green Fund without first consulting a professional advisor in order to ascertain whether the recommendation (if any) is appropriate, having regard to their investment objectives, financial situation and particular needs. Any opinions expressed are subject to change without notice and may not be updated by The Green Fund.

The Green Fund believes the information contained in this website is correct. All information, opinions, conclusions, estimates, reports or recommendations provided are included with due care to its accuracy; however, no representation or warranty is made as to their accuracy, completeness, or reliability.

The Green Fund disclaims all liability and responsibility for any direct or indirect loss, or damage, which may be incurred by any recipient through any information, omission, error, or inaccuracy contained within any report or recommendation.

The views expressed in any report or recommendation are those of the analyst writing the report and no part of the compensation received by the analyst is directly related to the inclusion of specific recommendations or opinions.

The Green Fund and / or its associates may hold interests in the entities mentioned in any posted report or recommendation.

The Green Fund, or its representatives, may have relationships with the companies mentioned in posted reports - for example, acting as corporate advisor, dealer, broker, or holder of principal positions. The Green Fund and / or its representatives may also transact in those securities mentioned in the report, in a manner not consistent with recommendations made in the report.

Any recommendations or opinions stated in a report are done so based on assumptions made by The Green Fund.

The information provided in any report and on which it is based may include projections and / or estimates which constitute forward-looking statements. These expressed beliefs of future performance, events, results, or returns may not eventuate and as such no guarantee of these future scenarios is given or implied by The Green Fund. Any forward looking statements are subject to uncertainties and risks that may mean those forecasts made by The Green Fund are materially different to actual events. Show Less